^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    safimaltib (JNJ-6633)

    i
    Other names: JNJ-6633, JNJ 67856633, JNJ-67856633
    Company:
    J&J
    Drug class:
    MALT1 protein inhibitor
    Related drugs:
    5ms
    A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=226, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    safimaltib (JNJ-6633)
    8ms
    A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL (clinicaltrials.gov)
    P1, N=45, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633)
    8ms
    A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=75, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed | Trial completion date: Apr 2025 --> Jan 2025 | Trial primary completion date: Apr 2025 --> Jan 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    safimaltib (JNJ-6633) • JNJ-4681
    10ms
    A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=226, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2026 --> Apr 2025
    Trial completion date
    |
    safimaltib (JNJ-6633)
    11ms
    A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring (clinicaltrials.gov)
    P1, N=80, Enrolling by invitation, Janssen Research & Development, LLC
    New P1 trial
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633) • JNJ-4681 • JNJ-6665 • JNJ-8902 • onametostat (JNJ-64619178) • rezetamig (JNJ-8780)
    12ms
    A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=226, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Dec 2024 --> Apr 2025
    Trial primary completion date
    |
    safimaltib (JNJ-6633)
    1year
    A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2026 --> Apr 2025 | Trial primary completion date: Nov 2024 --> Apr 2025
    Trial completion date • Trial primary completion date
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633)
    1year
    A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=75, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Dec 2026 --> Jul 2025
    Trial completion date • Combination therapy
    |
    safimaltib (JNJ-6633) • JNJ-4681
    over1year
    A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Nov 2024 --> Dec 2026
    Trial completion date
    |
    Imbruvica (ibrutinib) • safimaltib (JNJ-6633)
    over1year
    A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=75, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jul 2025 --> Dec 2026
    Trial completion date • Combination therapy
    |
    safimaltib (JNJ-6633) • JNJ-4681
    almost2years
    A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P1, N=75, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial primary completion date • Combination therapy
    |
    safimaltib (JNJ-6633) • JNJ-4681
    almost2years
    A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=226, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Oct 2023 --> Dec 2024
    Trial primary completion date
    |
    safimaltib (JNJ-6633)